INSYS Therapeutics Names New General Counsel
October 10 2018 - 6:00AM
INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the
development, manufacture and commercialization of pharmaceutical
cannabinoids and spray technology, today announced the addition of
Mark Nance to its senior management team as chief legal officer and
general counsel.
“As we continue to transform the company and advance the
pipeline strategically and with agility, Mark’s addition will be
critical to our executive leadership team,” said Saeed Motahari,
president and chief executive officer of INSYS Therapeutics. “Mark
brings to this position extensive experience in corporate legal
strategy, an in-depth understanding of the pharmaceutical industry
and an international perspective on business development that are
essential to our long-term success.”
Nance joins INSYS with nearly 20 years in general counsel roles
at both public and private companies in the pharmaceutical,
healthcare and technology sectors. He was recently the general
counsel for Mylan, N.V., a global pharmaceutical leader. Previously
he led the legal teams at G.E. Healthcare Medical Diagnostics and
G.E. Healthcare Life Sciences.
Nance also worked in the Office of Policy Planning at the U.S.
Federal Trade Commission and prior to attending law school served
as a commissioned officer in the U.S. Marine Corps. He holds
a J.D. from Cornell Law School and a B.A. in Political Science from
the University of Missouri.
Franc Del Fosse, the company’s current general counsel, will
transition to a new position as senior vice president of corporate
affairs and will work closely with Nance to ensure a seamless
transition.
About INSYS
INSYS Therapeutics is a specialty pharmaceutical
company that develops and commercializes innovative drugs and novel
drug delivery systems of therapeutic molecules that improve
patients’ quality of life. Using proprietary spray technology and
capabilities to develop pharmaceutical cannabinoids, INSYS is
developing a pipeline of products intended to address unmet medical
needs and the clinical shortcomings of existing commercial
products. INSYS is committed to developing medications for
potentially treating anaphylaxis, epilepsy, Prader-Willi syndrome,
opioid addiction and overdose, and other disease areas with a
significant unmet need.
Forward-Looking Statements
This press release contains forward-looking statements regarding
our belief that Mark Nance’s broad industry experience and his
expertise in legal strategy will contribute to our overall business
strategy and execution. These forward-looking statements are based
on management's expectations and assumptions as of the date of this
press release; actual results may differ materially from those in
these forward-looking statements as a result of various factors,
many of which are beyond our control. These factors include, but
are not limited to risk factors described in our filings with the
United States Securities and Exchange Commission, including those
factors discussed under the caption “Risk Factors” in our Annual
Report on Form 10-K for the year ended December 31, 2017 and
subsequent updates that may occur in our Quarterly Reports on Form
10-Q. Forward-looking statements speak only as of the date of this
press release and we undertake no obligation to publicly update or
revise these statements, except as may be required by law.
NOTE: All trademarks and registered trademarks are the property
of their respective owners.
CONTACT: |
Corporate Communications |
Investor Relations |
|
Joe McGrath |
Jackie Marcus or Chris Hodges |
|
INSYS Therapeutics |
Alpha IR Group |
|
480-500-3101 |
312-445-2870 |
|
jmcgrath@insysrx.com |
INSY@alpha-ir.com |
INSYS THERAPEUTICS, INC. (NASDAQ:INSY)
Historical Stock Chart
From Mar 2024 to Apr 2024
INSYS THERAPEUTICS, INC. (NASDAQ:INSY)
Historical Stock Chart
From Apr 2023 to Apr 2024